Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vision-Sciences Inc.

Division of Uroplasty Inc./Vision-Sciences Inc.
www.visionsciences.com

Latest From University of North Carolina

Start-Up Quarterly Statistics, Q3 2016

A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.

StartUps and SMEs Financing

Deals Shaping the Medical Industry, September 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Deals BioPharmaceutical

3D Printing: Will Personalized Medical Devices Be The Next Big Thing?

Medical device manufacturers have a growing interest in 3D printing, a technology that could upend the manufacturing and distribution of certain medical devices and expand the scope of personalized medicine – especially in orthopedics, where it's used for some models, implants, and surgical cutting guides. Despite uncertainties related to regulation, reimbursement, and scaling up, global 3D printing revenues for medical and dental applications reached an estimated $537.1 million in 2014.

Medical Device North America

G1 Therapeutics Inc.

Bone marrow suppression is arguably the worst side effect of chemotherapy, and to limit the damage chemotherapies do to healthy cells, clinicians now frequently follow protocols that call for supportive treatment with red blood cell stimulator EPO and/or GCSF. G1 Therapeutics Inc.’s drug candidate could one day displace growth factors by temporarily halting the growth of blood cells and their progenitors in the bone marrow so they can evade chemotherapies that target dividing cells.

BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Infection Control-Sterilization
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Uroplasty Inc.
  • Senior Management
  • Howard I Zauberman, Pres. & CEO
    Katherine Wolf, EVP, Corp. Dev. & CFO
    Gerald B Lichtenberger, PhD, VP, Bus. Dev.
    Carlos Babini, EVP, Global Sales & Mktg.
  • Contact Info
  • Vision-Sciences Inc.
    Phone: (845) 365-0600
    40 Ramland Road S.
    Orangeburg, NY 10962
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register